Navigation Links
Cephalon Completes Acquisition of Arana Therapeutics
Date:8/10/2009

FRAZER, Pa., Aug. 10 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has completed its previously announced acquisition of all of the outstanding ordinary shares of Australian biotechnology company, Arana Therapeutics Limited. As a result of the acquisition, Arana is now a wholly-owned subsidiary of Cephalon.

Cephalon Chairman and CEO, Frank Baldino Jr., Ph.D., said, "We are excited about the advanced biological and molecular technology expertise that Arana brings to Cephalon. With biologics in inflammatory diseases and clinical candidates in oncology for solid tumors, this acquisition will catalyze the entry of Cephalon into the biologics space."

Cephalon acquires an established protein engineering technology platform to transform proteins, including antibodies, into potent drug candidates. The lead biologic in the portfolio (ART621) is the first domain antibody to enter the clinic targeting TNF alpha, and is in a phase 2 clinical program for rheumatoid arthritis. Additional biologics acquired include: a RANKL inhibitor for bone metastases; one targeting a novel epitope for colorectal cancer in collaboration with Kyowa Hakko-Kirin; one targeting gangliosides for small cell lung cancer and melanoma; one targeting IL 12 /23 for psoriasis and Crohn's disease as well as other earlier stage opportunities.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe.
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... ... of FireflySci Inc. (FFS) in early 2015, the company continues to shake up the cuvette ... in a lab coat and Large Marge have been posted on the company’s Facebook page ... is proud to be the only cuvette manufacturer is the world that has an online ...
(Date:8/27/2015)... 2015 The National Necrotizing Fasciitis Foundation ... saved by doctors at Vanderbilt University Hospital in ... Pharmaceuticals and Dr. John Crew , director of ... Medical Center in Daly City, CA. ... approach, pioneered by Dr. Crew, that had previously saved ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its ... iLab Solutions as number 1,361 in growth for the three years through 2014. Being ... 0.1% fastest-growing privately held organizations in the country. , “We are thrilled to ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
... an explanation as to where and how North Sea oil ... be the first step on the way to developing improved ... from Danish oil fields. , A research group at the ... of Copenhagen has investigated drill cores collected from North Sea ...
... Apex Bioventures Acquisition Corporation (NYSE Amex: PEX ... notice from NYSE Amex LLC (the "Exchange") that the ... accepted by the Exchange and the Company has been ... compliance with the continued listing standards of the Exchange.As ...
... China, May 11 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ... CSKI ), a leading,fully integrated pharmaceutical company producing ... announced that it will conduct a,conference call at 10:00 ... to discuss its first quarter of fiscal year 2009 ...
Cached Biology Technology:New Danish research shows how oil gets stuck underground 2Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex 2China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 2China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 3
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... , 31 de julio de 2015 La 10 ... se celebrará por medio de BGI del 22 al 25 de ... Este año, la conferencia celebra su décimo ... ha convertido en una de las reuniones anuales más influyentes ... de las reuniones más dinámicas, entusiastas y mejores a nivel ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... New Rochelle, NY, December 2, 2010 For ... addressed at the highest level of government. With the ... the U.S. Department of Health and Human Services has ... - and supporting breastfeeding is prominent among them. ...
... scientists at the University of Leicester have recorded stunning ... European Space Agency satellite instruments have been observing ... points in space. Leicester scientists have used ... images of a snow-bound UK from observations on November ...
... of Chicago Medical Center is designed to offer surgeons ... new molecular and mechanical solutions to three age-old problems: ... between blood vessels), improving tissue healing after surgery and ... The conference, "Solving the most challenging surgical ...
Cached Biology News:New public health goals tackle obstacles to breastfeeding success 2Snow from space: University of Leicester releases satellite images of snow-bound UK 2Conference goals include better surgery and better surgeons 2Conference goals include better surgery and better surgeons 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Biology Products: